NO314501B1 - Tetrahydronaftofuranaminforbindelser, fremgangsmåte ved fremstilling deravog farmasöytiske sammensetninger inneholdende dem - Google Patents

Tetrahydronaftofuranaminforbindelser, fremgangsmåte ved fremstilling deravog farmasöytiske sammensetninger inneholdende dem Download PDF

Info

Publication number: NO314501B1
Authority: NO; Norway
Prior art keywords: ppm; formula; dihydrofuran; propylamino; tetrahydronaphtho
Prior art date: 1995-09-29

Application number

NO19964072A

Other languages

English (en)

Norwegian (no)

Other versions

NO964072D0 (no

NO964072L (no

Inventor

Jean-Louis Peglion

Joel Vian

Aimee Dessinges

Mark Millan

Valerie Audinot

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-29

Filing date

1996-09-27

Publication date

2003-03-31

1996-09-27 Application filed by Servier Lab filed Critical Servier Lab

1996-09-27 Publication of NO964072D0 publication Critical patent/NO964072D0/no

1997-04-01 Publication of NO964072L publication Critical patent/NO964072L/no

2003-03-31 Publication of NO314501B1 publication Critical patent/NO314501B1/no

Links

238000000034 method Methods 0.000 title claims description 17
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title claims description 5
-1 Tetrahydronaphthofuranamine Compounds Chemical class 0.000 title description 7
150000003839 salts Chemical class 0.000 claims abstract description 9
125000000217 alkyl group Chemical group 0.000 claims abstract description 8
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 4
239000002253 acid Substances 0.000 claims abstract description 3
230000003287 optical effect Effects 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 47
JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 46
229940095064 tartrate Drugs 0.000 claims description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 6
125000001309 chloro group Chemical group Cl* 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
230000002829 reductive effect Effects 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
239000000460 chlorine Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
VQXDQAATJUJGME-UHFFFAOYSA-N 5,6,7,8-tetrahydrobenzo[f][1]benzofuran-2-amine Chemical class C1CCCC2=C1C=C1C=C(N)OC1=C2 VQXDQAATJUJGME-UHFFFAOYSA-N 0.000 claims description 3
208000018737 Parkinson disease Diseases 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
238000011282 treatment Methods 0.000 claims description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
206010013654 Drug abuse Diseases 0.000 claims description 2
208000026139 Memory disease Diseases 0.000 claims description 2
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 claims description 2
229910052740 iodine Chemical group 0.000 claims description 2
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
208000028017 Psychotic disease Diseases 0.000 claims 1
125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
239000000155 melt Substances 0.000 description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
239000000047 product Substances 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
238000007429 general method Methods 0.000 description 18
238000005481 NMR spectroscopy Methods 0.000 description 17
238000001228 spectrum Methods 0.000 description 17
NTBIYBAYFBNTCD-UHFFFAOYSA-N dibenzoyl 2,3-dihydroxybutanedioate Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=CC=C1 NTBIYBAYFBNTCD-UHFFFAOYSA-N 0.000 description 16
108020003175 receptors Proteins 0.000 description 16
102000005962 receptors Human genes 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 8
230000003291 dopaminomimetic effect Effects 0.000 description 8
235000019441 ethanol Nutrition 0.000 description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000003480 eluent Substances 0.000 description 6
238000003818 flash chromatography Methods 0.000 description 6
WUAXWQRULBZETB-UHFFFAOYSA-N homoveratric acid Chemical compound COC1=CC=C(CC(O)=O)C=C1OC WUAXWQRULBZETB-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000000377 silicon dioxide Substances 0.000 description 6
LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 5
HJQLFCDMISYAIO-UHFFFAOYSA-N 3,3-dicyclopropylpropanoyl chloride Chemical compound C1CC1C(CC(=O)Cl)C1CC1 HJQLFCDMISYAIO-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
230000027455 binding Effects 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
229910000041 hydrogen chloride Inorganic materials 0.000 description 4
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
239000012280 lithium aluminium hydride Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 4
VARVNFDGRLLTCI-UHFFFAOYSA-N 2-(4-phenoxyphenyl)acetic acid Chemical group C1=CC(CC(=O)O)=CC=C1OC1=CC=CC=C1 VARVNFDGRLLTCI-UHFFFAOYSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
ZTICGZOOKCTTML-UHFFFAOYSA-N 2-cyclobutylacetyl chloride Chemical compound ClC(=O)CC1CCC1 ZTICGZOOKCTTML-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
101150049660 DRD2 gene Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
239000013078 crystal Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
108010024941 iodothyronine deiodinase type II Proteins 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
HPXJIGZLXHQSGU-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3-dihydroindol-2-one Chemical compound ClCCC1=CC=C2NC(=O)CC2=C1 HPXJIGZLXHQSGU-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000012190 activator Substances 0.000 description 2
150000001412 amines Chemical group 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
AYEGPMGNMOIHDL-IUYQGCFVSA-N (1r,2s)-2-methylcyclopropane-1-carboxylic acid Chemical compound C[C@H]1C[C@H]1C(O)=O AYEGPMGNMOIHDL-IUYQGCFVSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
DEFNUDNHTUZJAL-UHFFFAOYSA-N 1-bromo-2-methylprop-1-ene Chemical compound CC(C)=CBr DEFNUDNHTUZJAL-UHFFFAOYSA-N 0.000 description 1
AVMHMVJVHYGDOO-UHFFFAOYSA-N 1-bromobut-2-ene Chemical compound CC=CCBr AVMHMVJVHYGDOO-UHFFFAOYSA-N 0.000 description 1
LLZKAZNUCYYBQO-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)acetic acid Chemical group OC(=O)CC1=CC=CC(OCC=2C=CC=CC=2)=C1 LLZKAZNUCYYBQO-UHFFFAOYSA-N 0.000 description 1
MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
HWTMLSYLXGLSDF-UHFFFAOYSA-N 2-(4-phenylphenyl)acetyl chloride Chemical compound C1=CC(CC(=O)Cl)=CC=C1C1=CC=CC=C1 HWTMLSYLXGLSDF-UHFFFAOYSA-N 0.000 description 1
QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
KVAFNOAGIQWNSJ-UHFFFAOYSA-N 2-[3,4-bis(phenylmethoxy)phenyl]acetic acid Chemical compound C=1C=CC=CC=1COC1=CC(CC(=O)O)=CC=C1OCC1=CC=CC=C1 KVAFNOAGIQWNSJ-UHFFFAOYSA-N 0.000 description 1
VABYVFZVTIDNOA-UHFFFAOYSA-N 2-cyclohexylacetyl chloride Chemical compound ClC(=O)CC1CCCCC1 VABYVFZVTIDNOA-UHFFFAOYSA-N 0.000 description 1
NILLIUYSJFTTRH-UHFFFAOYSA-N 2-cyclopentylacetyl chloride Chemical compound ClC(=O)CC1CCCC1 NILLIUYSJFTTRH-UHFFFAOYSA-N 0.000 description 1
IALGRRFZGRXFKT-UHFFFAOYSA-N 2-cyclopropylacetyl chloride Chemical compound ClC(=O)CC1CC1 IALGRRFZGRXFKT-UHFFFAOYSA-N 0.000 description 1
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
CGVQZQXOSGSXTC-UHFFFAOYSA-N 4-bromobenzamide;butanal Chemical compound CCCC=O.NC(=O)C1=CC=C(Br)C=C1 CGVQZQXOSGSXTC-UHFFFAOYSA-N 0.000 description 1
VNDHYTGVCGVETQ-UHFFFAOYSA-N 4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C=C1 VNDHYTGVCGVETQ-UHFFFAOYSA-N 0.000 description 1
HESAUDVOEDNIKE-UHFFFAOYSA-N 5-(3-chloropropyl)-1,3-dihydroindol-2-one Chemical compound ClCCCC1=CC=C2NC(=O)CC2=C1 HESAUDVOEDNIKE-UHFFFAOYSA-N 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
238000007126 N-alkylation reaction Methods 0.000 description 1
LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
108010035235 Phleomycins Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002539 anti-aggressive effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
GMLFPSKPTROTFV-UHFFFAOYSA-N dimethylborane Chemical compound CBC GMLFPSKPTROTFV-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
UTVVREMVDJTZAC-UHFFFAOYSA-N furan-2-amine Chemical class NC1=CC=CO1 UTVVREMVDJTZAC-UHFFFAOYSA-N 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
210000001756 lactotroph Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000001095 motoneuron effect Effects 0.000 description 1
AZTCBYBLWUXCCG-UHFFFAOYSA-N n-[4-(3-iodopropyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(CCCI)C=C1 AZTCBYBLWUXCCG-UHFFFAOYSA-N 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Furan Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

NO19964072A 1995-09-29 1996-09-27 Tetrahydronaftofuranaminforbindelser, fremgangsmåte ved fremstilling deravog farmasöytiske sammensetninger inneholdende dem NO314501B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9511446A FR2739379B1 (fr)	1995-09-29	1995-09-29	Nouveaux composes amines de 5,6,7,8-tetrahydronaphto(2,3-b) furane et d'indano(5,6-b)furane, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number	Publication Date
NO964072D0 NO964072D0 (no)	1996-09-27
NO964072L NO964072L (no)	1997-04-01
NO314501B1 true NO314501B1 (no)	2003-03-31

Family

ID=9483043

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19964072A NO314501B1 (no)	1995-09-29	1996-09-27	Tetrahydronaftofuranaminforbindelser, fremgangsmåte ved fremstilling deravog farmasöytiske sammensetninger inneholdende dem

Country Status (15)

Country	Link
US (1)	US5665765A (de)
EP (1)	EP0765877B1 (de)
JP (1)	JPH09110855A (de)
CN (1)	CN1075067C (de)
AT (1)	ATE256675T1 (de)
AU (1)	AU707883B2 (de)
CA (1)	CA2186337C (de)
DE (1)	DE69631104T2 (de)
DK (1)	DK0765877T3 (de)
ES (1)	ES2213171T3 (de)
FR (1)	FR2739379B1 (de)
NO (1)	NO314501B1 (de)
NZ (1)	NZ299465A (de)
PT (1)	PT765877E (de)
ZA (1)	ZA968167B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7216866B2 (en) *	2003-04-28	2007-05-15	Kyocera Mita Corporation	Sheet transport path switching mechanism
CN116209657A (zh) *	2020-08-06	2023-06-02	泰科根公司	用于精神障碍或增强的2-氨基茚满化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4470990A (en) *	1983-03-14	1984-09-11	Ayerst, Mckenna & Harrison Inc.	6,7,8,9-Tetrahydronaphtho(1,2-B)furan-8-amine derivatives and their use as dopamine receptor stimulants
FR2613364B1 (fr) *	1987-04-01	1989-06-09	Adir	Nouvelles amines tricycliques derivees du tetrahydro-5, 6, 7, 8 naphto (2, 3b) dihydro-2, 3 furanne, et du tetrahydro-6, 7, 8, 9 5h-benzocyclohepta (2, 3b) dihydro-2, 3 furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2613365B1 (fr) *	1987-04-01	1989-07-28	Adir	Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2725985B1 (fr) *	1994-10-21	1996-11-15	Adir	Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

1995
- 1995-09-29 FR FR9511446A patent/FR2739379B1/fr not_active Expired - Fee Related
1996
- 1996-09-24 CA CA002186337A patent/CA2186337C/fr not_active Expired - Fee Related
- 1996-09-26 PT PT96402044T patent/PT765877E/pt unknown
- 1996-09-26 DK DK96402044T patent/DK0765877T3/da active
- 1996-09-26 ES ES96402044T patent/ES2213171T3/es not_active Expired - Lifetime
- 1996-09-26 EP EP96402044A patent/EP0765877B1/de not_active Expired - Lifetime
- 1996-09-26 DE DE69631104T patent/DE69631104T2/de not_active Expired - Fee Related
- 1996-09-26 AT AT96402044T patent/ATE256675T1/de not_active IP Right Cessation
- 1996-09-27 ZA ZA968167A patent/ZA968167B/xx unknown
- 1996-09-27 NZ NZ299465A patent/NZ299465A/en unknown
- 1996-09-27 NO NO19964072A patent/NO314501B1/no not_active IP Right Cessation
- 1996-09-27 CN CN96113084A patent/CN1075067C/zh not_active Expired - Fee Related
- 1996-09-27 US US08/720,039 patent/US5665765A/en not_active Expired - Fee Related
- 1996-09-27 AU AU65897/96A patent/AU707883B2/en not_active Ceased
- 1996-09-30 JP JP8258217A patent/JPH09110855A/ja active Pending

Also Published As

Publication number	Publication date
ES2213171T3 (es)	2004-08-16
FR2739379A1 (fr)	1997-04-04
AU707883B2 (en)	1999-07-22
NO964072D0 (no)	1996-09-27
CA2186337C (fr)	2002-01-01
JPH09110855A (ja)	1997-04-28
ATE256675T1 (de)	2004-01-15
DE69631104D1 (de)	2004-01-29
EP0765877B1 (de)	2003-12-17
CN1075067C (zh)	2001-11-21
AU6589796A (en)	1997-04-10
NZ299465A (en)	1997-06-24
PT765877E (pt)	2004-04-30
US5665765A (en)	1997-09-09
CN1150151A (zh)	1997-05-21
FR2739379B1 (fr)	1997-10-24
EP0765877A1 (de)	1997-04-02
NO964072L (no)	1997-04-01
DE69631104T2 (de)	2004-09-02
DK0765877T3 (da)	2004-04-19
ZA968167B (en)	1997-05-02
CA2186337A1 (fr)	1997-03-30

Legal Events

Date	Code	Title	Description
2005-06-20	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
FI95246C (fi)	1996-01-10	Menetelmä terapeuttisesti käyttökelpoisten, substituoitujen aminometyylibentsodihydropyraanien ja aminometyyli(di- ja tetra)hydronaftaleenien valmistamiseksi
CA1341024C (en)	2000-06-13	Benzo-fused cycloalkane and oxa- and thia-, cycloalkane trans-1, 2-diamine derivatives
CA2958625C (en)	2019-05-28	Crystal of pyrrole derivative and method for producing the same
MXPA02001986A (es)	2002-10-31	Nuevos derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopamina.
WO2020112941A2 (en)	2020-06-04	Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
NO174421B (no)	1994-01-24	Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelsen 11-(4-(2-(2-hydroksyetoksy)-etyl)-1-piperazinyl)-dibenzo(b,f)(1,4)-tiazepin
MX2007001854A (es)	2007-03-28	Hidratos de polimorfos de 4-[[(7 -r)-8- ciclopentil-7 -etil-5, 6, 7, 8-tetrahidro-5 -metil-4-6 -oxo-2-piperidinil] amino]-3 -metoxi-n- (1-metil-4 -piperidinil)-benzamida, metodos para la produccion de los mismos, y uso de los mismos como medicamentos
AU2015226679B2 (en)	2017-05-25	Piperidine derivatives as orexin receptor antagonist
NO322666B1 (no)	2006-11-13	Substituerte fenyl-piperazinderivater, farmasoytiske sammensetninger inneholdende disse og deres anvendelse
EP1720861A2 (de)	2006-11-15	Antagonisten des histamin-h3-rezeptors, herstellung und therapeutische anwendungen
EP1680416A2 (de)	2006-07-19	Naphthalin-1,5-disulfonsäuresalze einer substituierten 4-amino-1-(pyridylmethyl)piperidinverbindung
NZ227739A (en)	1990-08-28	Substituted 1,4-benzoxazine and benzothiazine derivatives and pharmaceutical compositions; processes for preparation
NO314501B1 (no)	2003-03-31	Tetrahydronaftofuranaminforbindelser, fremgangsmåte ved fremstilling deravog farmasöytiske sammensetninger inneholdende dem
US20040034036A1 (en)	2004-02-19	N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
DE69517768T2 (de)	2001-03-01	IMIDAZOLYLALKYLDERIVATE VON IMIDAZO [5,1-c][1,4]BENZOXAZIN-1-ON UND IHRE VERWENDUNG ALS ARZNEIMITTEL
US11407759B2 (en)	2022-08-09	Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
JP2009523806A (ja)	2009-06-25	（４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
WO2002002529A1 (de)	2002-01-10	Bicyclische lactame und sulfonamide mit 5-ht1a-affinität und ihre verwendung zur prophylaxe und therapie der zerebralen ischämie
CN119462657A (zh)	2025-02-18	一种氮杂麦角林类衍生物、其药物组合物和其应用
EA045390B1 (ru)	2023-11-22	Способ синтеза фуроимидазопиридинового соединения, кристаллическая форма фуроимидазопиридинового соединения и кристаллическая форма его соли
HK1221214B (en)	2019-01-11	Method for preparing an atropisomer of a pyrrole derivative
CZ2001225A3 (cs)	2001-05-16	Derivát bifenylu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje